India  

Gilead says remdesivir cuts death risk

Video Credit: Reuters Studio - Duration: 01:04s - Published
Gilead says remdesivir cuts death risk

Gilead says remdesivir cuts death risk

Gilead Sciences said Friday additional data from a late-stage study showed its antiviral remdesivir reduced the risk of death and significantly improved the conditions of severely ill COVID-19 patients.

Fred Katayama reports.

0
shares
ShareTweetSavePostSend
 

πŸ’‘ newsR Knowledge: Other News Mentions

Gilead Sciences American pharmaceutical company

Drugmaker Says Remdesivir Can Lower COVID-19 Death Risk By 62% [Video]

Drugmaker Says Remdesivir Can Lower COVID-19 Death Risk By 62%

The antiviral drug Remdesivir has proven to be effective in the treatment of COVID-19. According to UPI, the drug can lower the risk of death in COVID-19 patients by 62%. U.S. drugmaker Gilead Sciences reported the new data on Friday. Gilead said the results came from a comparative analysis among 312 patients in its Phase 3 clinical trial. There have been over 3.4 million confirmed cases of coronavirus in the U.S., with a death toll of 138,247 people.

Credit: Wochit News    Duration: 00:32Published
Gilead sparks Wall Street rally [Video]

Gilead sparks Wall Street rally

U.S. stocks rose Friday as a positive analysis on Gilead Sciences Inc's antiviral drug to treat COVID-19 helped to soothe investor worries over a record rise in coronavirus cases in the United States. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:20Published
Gilead's remdesivir gets conditional EU clearance [Video]

Gilead's remdesivir gets conditional EU clearance

The European Commission said Friday it had given conditional approval for the use of antiviral drug remdesivir in severe COVID-19 patients. As Fred Katayama reports, that makes it the region's first authorized therapy to treat the virus.

Credit: Reuters Studio    Duration: 00:59Published
Gilead to Charge $3,120 Per Patient for Typical Covid-19 Treatment [Video]

Gilead to Charge $3,120 Per Patient for Typical Covid-19 Treatment

Gilead is the pharmaceutical company behind a drug that’s been approved for COVID emergencies. The FDA officially announced the medicine could be used in treating COVID-19 patients. Gilead has now announced the drug will cost $3,120 per typical treatment course for insured individuals. Research has indicated the drug could cut the recovery time for hospitalized COVID-19 patients. It could shorten satsy by several days, reports Gizmodo.

Credit: Wochit News    Duration: 00:35Published

Fred Katayama journalist

Crisis containment makes Europe alluring: strategist [Video]

Crisis containment makes Europe alluring: strategist

RiverFront Investment's Chris Konstantinos says investors should get exposure to Europe partly because it has done a good job of containing the health crisis, enabling manufacturing to rebound. He tells Reuters' Fred Katayama why Germany is particularly attractive.

Credit: Reuters Studio    Duration: 05:21Published
Uber rides plunge but food delivery doubles [Video]

Uber rides plunge but food delivery doubles

Homebound customers of Uber Technologies more than doubled their orders from the company's food-delivery service in the second quarter but demand for ride-hailing trips only marginally recovered from pandemic rock-bottom. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:21Published
Trim exposure to Apple, Microsoft: strategist [Video]

Trim exposure to Apple, Microsoft: strategist

Crossmark Global Investments' Victoria Fernandez is still bullish about tech stocks, but she says investors should take some profits on the big names. She tells Reuters' Fred Katayama investors should put the proceeds into Walmart, McCormick and JPMorgan Chase.

Credit: Reuters Studio    Duration: 04:46Published
Bezos sells Amazon shares worth $3.1 bln [Video]

Bezos sells Amazon shares worth $3.1 bln

Amazon.com Jeff Bezos sold shares worth $3.1 billion in the e-commerce company in recent days, regulatory filings showed on Wednesday. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:08Published

You Might Like


Tweets about this